Last reviewed · How we verify
grazoprevir and elbasvir
Grazoprevir and elbasvir is a marketed drug developed by Taoyuan General Hospital, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | grazoprevir and elbasvir |
|---|---|
| Sponsor | Taoyuan General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma (PHASE2)
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. (PHASE3)
- Zepatier in Patients with Substance Use
- HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant (PHASE4)
- Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (PHASE1, PHASE2)
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (PHASE2)
- Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (PHASE4)
- ATTIC - Access To Treat in the Community (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- grazoprevir and elbasvir CI brief — competitive landscape report
- grazoprevir and elbasvir updates RSS · CI watch RSS
- Taoyuan General Hospital portfolio CI